News

Proteolysis is the enzymatic process by which proteins are degraded into their component polypeptide or amino acid parts. This generally occurs through protease-mediated hydrolysis of peptide ...
A new strategy for delivering bulky PROTACs to cancerous cells successfully utilizes the CD36 protein pathway on cells’ surfaces.
BioTheryX’s technology platform centers on targeted protein degradation, including PHM ‘molecular glues’, PROteolysis TArgeting Chimeras (PROTACs/PTCs) and monovalent degraders that enable ...
ARV-393 is Arvinas' investigational PROteolysis TArgeting Chimera (PROTAC) degrader targeting the B-cell lymphoma 6 protein ...
In a recent study published in the journal Nature, researchers from the United States of America developed the synthetic intramembrane proteolysis receptor (SNIPR) architecture to activate ...
Arvinas to present preclinical data for PROTAC BCL6 degrader & ARV-393 at 2025 AACR annual meeting in Chicago: New Haven, Connecticut Wednesday, April 23, 2025, 18:00 Hrs [IST] Ar ...